Dr. Kelly Ross, MD

Claim this profile

West Virginia University Hospitals Inc

Studies Infusion Reaction
Studies Intestinal Maturation
4 reported clinical trials
11 drugs studied

Area of expertise

1

Infusion Reaction

Kelly Ross, MD has run 1 trial for Infusion Reaction.

2

Intestinal Maturation

Kelly Ross, MD has run 1 trial for Intestinal Maturation. Some of their research focus areas include:

t(8;21) negative
inv(16) negative
t(16;16) negative

Affiliated Hospitals

Image of trial facility.

West Virginia University Hospitals Inc.

Image of trial facility.

West Virginia University

Clinical Trials Kelly Ross, MD is currently running

Image of trial facility.

Inotuzumab + Blinatumomab

for Acute Lymphoblastic Leukemia

This phase II trial studies how well inotuzumab ozogamicin and blinatumomab with or without ponatinib work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly diagnosed, has come back after a period of improvement (recurrent), or does not respond to treatment (refractory). Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a chemotherapy drug, called ozogamicin. Inotuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD22 receptors, and delivers ozogamicin to kill them. Blinatumomab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Ponatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving inotuzumab ozogamicin and blinatumomab with or without ponatinib may be effective in treating patients with newly diagnosed, recurrent or refractory CD22 positive B-lineage acute lymphoblastic leukemia.

Recruiting

1 award

Phase 2

10 criteria

Image of trial facility.

Unlicensed Cord Blood Transplant

for Blood/Immune System Disorders

This trial is testing the safety of giving patients special blood from umbilical cords. The study focuses on patients who receive these infusions to see if there are any serious side effects. The cord blood has special cells that can help make new blood cells in the body. Umbilical cord blood has been used in the treatment of various diseases for many years, including leukemia, lymphoma, and congenital immunodeficiency.

Recruiting

1 award

Phase 2

1 criteria

More about Kelly Ross, MD

Clinical Trial Related

7 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Kelly Ross, MD has experience with

  • Unlicensed CBU
  • Cytarabine
  • Daunorubicin
  • Gilteritinib
  • Midostaurin
  • Dasatinib

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Kelly Ross, MD specialize in?

Is Kelly Ross, MD currently recruiting for clinical trials?

Are there any treatments that Kelly Ross, MD has studied deeply?

What is the best way to schedule an appointment with Kelly Ross, MD?

What is the office address of Kelly Ross, MD?

Is there any support for travel costs?